Current concerns about multiresistance and a diminishing antibiotic pipeline are mainly addressed to Gram-negative bacteria. The greatest fear within the Gram-positive arena is vancomycin-resistant Staphylococcus aureus. Its epidemiology and clinical presentation give cause for concern, but so far its impact has been strictly limited. While this may change, the loss of glycopeptides as a treatment option may not, in fact, be all bad news.
No takes yet. Share an insight, caveat, or question.
I.M. Gould (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: